Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir to Reduce T Cell Activation in HIV Infection
NCT00264290Phase 4Completed
- Sponsor
- University of California, San Francisco
- Start
- Aug 2006
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of valganciclovir in cytomegalovirus infection (CMV), sponsored by University of California, San Francisco. Started Aug 2006; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00264290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00264290.